Ron Christopher, PhD, DABT, FCP is Head of Clinical Pharmacology and Toxicology supporting the novel non-opioid small molecule SRP-3D (DA). He has written the pharmacology/toxicology and clinical pharmacology sections for global regulatory submissions, including pre-IND packages, IND/CTA, BLA/NDA/MAA packages as well as investigator brochures and annual reports. Ron has over 30 years’ experience in the pharmaceutical and biotech industries with extensive experience in pharmaceutical and biopharmaceutical industry research and development. He received his doctorate in Veterinary Toxicology from Texas A&M University and is a Diplomate of the American Board of Toxicology (2003) and Fellow, American College of Clinical Pharmacology (2011). Ron is a full member of the Society of Toxicology (SOT), American College of Toxicology (ACT), and American Society for Clinical Pharmacology & Therapeutics (ASCPT). In his most recent role, he was Vice President, Drug Development at Arena Pharmaceuticals, Inc. (San Diego, CA) and was responsible for drug safety, drug disposition and early clinical development activities supporting metabolic, cardiovascular, CNS and autoimmune therapeutic areas. Prior to joining Arena Pharmaceuticals, Ron has served in various leadership roles within the research and development industry, to include Takeda Pharmaceuticals, Johnson & Johnson, Schering-Plough, Bayer, and Ligand Pharmaceuticals. Ron has supported with teaching at the University of California, San Diego Skaggs School of Pharmacy in an adjunct professor role and has published more than 75 original peer-reviewed publications, conference abstracts and chapters in the areas of pharmacology, drug metabolism, pharmacokinetics, exposure-response modeling, biopharmaceutics, and drug-drug interactions in therapeutic areas of oncology, CNS, inflammation and metabolic research. Ron holds a B.S. in pathobiology from The University of Connecticut (Storrs).